Insider Monkey
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval
📈
AI Sentiment
Highly Positive
8/10
- Home
- COGT
as of 03-06-2026 3:39pm EST
$37.08
$0.38
-1.01%
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 6.5B | IPO Year: | 2018 |
| Target Price: | $33.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.16 | EPS Growth: | -11.34 |
| 52 Week Low/High: | $3.72 - $43.73 | Next Earning Date: | 05-22-2026 |
| Revenue: | $7,871,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1180.55% |
| P/E Ratio: | -17.30 | Index: | N/A |
| Free Cash Flow: | -265998000.0 | FCF Growth: | N/A |
AI-Powered COGT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 75.63%
75.63%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cogent Biosciences Inc. (COGT)
Fairmount Funds Management LLC
Sell
Director
COGT Jan 22, 2026
Avg Cost/Share
$36.40
Shares
3,500,000
Total Value
$127,400,000.00
Owned After
5,503,418
SEC Form 4
Robinson John Edward
Sell
Chief Scientific Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.74
Shares
90,000
Total Value
$3,486,600.00
Owned After
140,002
SEC Form 4
Green John L.
Sell
Chief Financial Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.68
Shares
77,000
Total Value
$2,978,360.00
Owned After
131,834
SEC Form 4
Kearns Evan
Sell
Chief Legal Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.70
Shares
65,000
Total Value
$2,515,500.00
Owned After
109,398
SEC Form 4
Sachs Jessica
Sell
Chief Medical Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.70
Shares
82,642
Total Value
$3,198,245.40
Owned After
133,938
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | COGT | Director | Jan 22, 2026 | Sell | $36.40 | 3,500,000 | $127,400,000.00 | 5,503,418 | |
| Robinson John Edward | COGT | Chief Scientific Officer | Dec 26, 2025 | Sell | $38.74 | 90,000 | $3,486,600.00 | 140,002 | |
| Green John L. | COGT | Chief Financial Officer | Dec 26, 2025 | Sell | $38.68 | 77,000 | $2,978,360.00 | 131,834 | |
| Kearns Evan | COGT | Chief Legal Officer | Dec 26, 2025 | Sell | $38.70 | 65,000 | $2,515,500.00 | 109,398 | |
| Sachs Jessica | COGT | Chief Medical Officer | Dec 26, 2025 | Sell | $38.70 | 82,642 | $3,198,245.40 | 133,938 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 17, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 17, 2026 · 100% conf.
AI Prediction SELL
1D
-2.01%
$36.86
5D
-9.70%
$33.97
20D
-4.11%
$36.07
Price: $37.62 Prob +5D: 0% AUC: 1.000
0001193125-26-053131
8-K
0001622229False00016222292026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2026
COGENT BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38443
46-5308248
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
275 Wyman Street, 3rd Floor Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 945-5576 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.001 Par Value
COGT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 17, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Cogent Biosciences, Inc. on February 17, 2026, furnished herewith.
104
The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 17, 2026
COGENT BIOSCIENCES, INC.
By:
/s/ John Green
John Green
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001193125-25-261797
8-K
False000162222900016222292025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2025
COGENT BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38443
46-5308248
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
275 Wyman Street, 3rd Floor Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 945-5576 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.001 Par Value
COGT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 3, 2025, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Cogent Biosciences, Inc. on November 3, 2025, furnished herewith.
104
The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 3, 2025
COGENT BIOSCIENCES, INC.
By:
/s/ John Green
John Green
Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0000950170-25-102433
8-K
False000162222900016222292025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025
COGENT BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38443
46-5308248
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
275 Wyman Street, 3rd Floor Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 945-5576 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.001 Par Value
COGT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 5, 2025, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Cogent Biosciences, Inc. on August 5, 2025, furnished herewith.
104
The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2025
COGENT BIOSCIENCES, INC.
By:
/s/ John Green
John Green
Chief Financial Officer
Latest Cogent Biosciences Inc. News
COGT Breaking Stock News: Dive into COGT Ticker-Specific Updates for Smart Investing
GlobeNewswire
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
📈
AI Sentiment
Highly Positive
9/10
Compare COGT vs Leading Stocks
See how COGT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COGT Cogent Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.